Welcome to our dedicated page for Actuate Therapeutics SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Actuate Therapeutics, Inc. (NASDAQ: ACTU) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission documents, along with AI-powered tools to help interpret complex regulatory disclosures. As a clinical-stage biopharmaceutical company and emerging growth company, Actuate uses SEC filings to describe its oncology pipeline, capital-raising activities, and key risks associated with developing elraglusib, its lead GSK-3β inhibitor.
Investors can review current and periodic reports, including Forms 8-K that detail material events. For example, Actuate has filed 8-Ks describing a June 2025 securities purchase agreement for a private placement of common stock and warrants, a registration rights agreement for those securities, and a September 2025 underwriting agreement for a public offering of common stock under an effective Form S-3 shelf registration statement. Another 8-K outlines the company’s use of its website, SEC filings, press releases, and social media accounts as disclosure channels.
Registration statements such as the Form S-1 filed in July 2025 provide additional background on Actuate’s business. In that document, the company explains that it is a clinical-stage biopharmaceutical company focused on high-impact, difficult-to-treat cancers through inhibition of glycogen synthase kinase-3, and describes elraglusib as an ATP-competitive small molecule designed to block GSK-3β and affect tumor survival and anti-tumor immunity.
On Stock Titan, users can access these filings as they are made available through EDGAR and use AI-generated summaries to quickly identify key points, such as financing terms, development strategy, and risk factor themes. The filings page is also a starting point for tracking future annual reports on Form 10-K, quarterly reports on Form 10-Q, and beneficial ownership or insider transaction reports on Form 4 when they are filed, helping investors build a more complete picture of ACTU’s regulatory and financial profile.
ACTUATE THERAPEUTICS, INC. director Dr. Martin H. Huber Jr. reported an initial holding of non-qualified stock options on Common Stock. He was granted 30,000 stock options upon joining the Board of Directors, with an exercise price of $3.00 per share and expiration on May 1, 2036.
The grant vests in three equal installments on the first, second, and third anniversaries of the grant date, contingent on his continued service. Following this grant, he holds derivative rights over 30,000 underlying shares through these options, representing equity-based compensation rather than an open-market trade.
Actuate Therapeutics, Inc. appointed Martin H. Huber, MD, as an independent director and expanded its Board from seven to eight members. He will serve as a Class III director until the 2027 annual meeting and join the Nominating and Corporate Governance Committee.
Dr. Huber will participate in the non-employee Director Compensation Program, including stock options to purchase 30,000 common shares vesting over three years and an annual cash retainer of $44,000, paid quarterly. A separate consulting agreement provides a $3,000 quarterly fee for additional R&D advisory services.
The accompanying press release highlights Actuate’s focus on developing elraglusib for difficult-to-treat cancers and reiterates risk factors, including that its financial condition raises substantial doubt about its ability to continue as a going concern without additional capital beyond the second quarter of fiscal 2026.
Voss Capital and affiliated entities report beneficial ownership stakes in Actuate Therapeutics. The filing states that Voss Capital (through managed accounts and funds) may be deemed to beneficially own 1,814,263 shares, representing approximately 7.65% of Actuate's outstanding common stock. The report breaks this total into holdings including Voss Value Master Fund: 300,000 shares, Voss Value-Oriented Special Situations Fund: 50,000 shares, and Voss Advisors GP (as GP): 350,000 shares. Shares outstanding are reported as 23,709,943 as of March 25, 2026.
Actuate Therapeutics, Inc. is holding its 2026 virtual annual meeting of stockholders on May 21, 2026 at 11:00 a.m. EDT to elect two Class II directors and ratify Crowe LLP as independent auditor for 2026.
Stockholders of record as of March 24, 2026, holding 23,704,691 common shares, may vote online, by phone, mail or during the webcast. The proxy also details corporate governance practices, committee structures and 2025 executive pay, including salary, cash bonuses and equity awards under the 2024 Stock Incentive Plan.
Actuate Therapeutics reported that President and CEO Daniel M. Schmitt received a grant of employee stock options covering 237,000 shares of common stock. The options have an exercise price of $2.49 per share and expire on April 1, 2036.
All 237,000 options are shown as held directly following the transaction. According to the grant terms, 25% of the options will vest on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months.
ACTUATE THERAPEUTICS, INC. reported that Chief Operating Officer Andrew Paul Mazar received an employee stock option grant for 105,000 options to buy common stock at an exercise price of $2.49 per share.
The options expire on April 1, 2036. According to the vesting terms, 25% of the grant will vest on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, he holds 105,000 derivative securities directly.
ACTUATE THERAPEUTICS, INC. Chief Financial Officer Paul J. Lytle received an equity compensation grant of employee stock options for 105,000 shares of common stock. The options have an exercise price of $2.49 per share and expire on April 1, 2036.
These options will vest 25% on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months. The filing reflects a compensation-related award rather than an open-market stock purchase or sale.
Actuate Therapeutics’ Annual Report focuses on elraglusib, its lead GSK‑3β inhibitor, and strong Phase 2 data in metastatic pancreatic ductal adenocarcinoma (mPDAC). In a 286‑patient trial, elraglusib plus gemcitabine/nab‑paclitaxel achieved median overall survival of 10.1 months versus 7.2 months on chemotherapy alone (hazard ratio 0.62, p=0.02).
The 12‑month survival rate nearly doubled to 44.4% from 22.3%, with 24‑month survival rising to 12.9% from 2.6%, while safety was broadly consistent with the control arm. The company is planning Phase 3 global registration discussions with the FDA and EMA and is also advancing elraglusib in pediatric cancers and developing a highly bioavailable oral tablet for additional solid tumor indications.
Actuate remains a clinical‑stage company with no approved products, significant ongoing losses, and a need for substantial additional capital. As of June 30, 2025, non‑affiliate market value was about $42.1 million, and 23,709,943 shares were outstanding as of March 25, 2026.
Actuate Therapeutics, Inc. President and CEO Daniel M. Schmitt reported the vesting and settlement of 272,055 restricted stock units on February 13, 2026, converting into the same number of common shares at $0 per share. To cover federal and state withholding taxes, the issuer withheld 121,874 shares of common stock valued at $4.33 per share, leaving Schmitt with 150,181 directly held common shares and 272,056 RSUs outstanding. He also reports indirect ownership of additional common shares through several irrevocable family trusts for which he serves as trustee.